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jligh-Sensitivity Serum Calcitonin Assays Applied to Screening for 
Xhyroid C-Cell Disease in Multiple Endocrine Neoplasia Type 2A* 
ivlichael M. Kaplan,* Glenn M. Stall,* Timothy Cummings,' Andrew MacAulay,* 
Philippe Motte,* Hubert J. Wolfe,^  Seymour Reichiin,* and Arman H. Tashjian, Jril 
Two serum calcitonin assays with sensitivities <, 10 pglmL were compared to our standard 
radioimmimoa.ssay (sensitivity 100 pg/mL) in multiple endocrine neoplasia type 2A (MEN 2A) 
screening. Values from the Nichols displacement radioimmunoas.say averaged 38%: higher than 
values from the CIS immunoradiometric assay; values from hoth were highly correlated, r = 0.845. In 
three individuals, both oftlie newer as.says revealed abnormalities in pentagastrin tests three to four 
years before abnormalities were detected by the standard assay. Pentaga.strin tests after total 
thyroidectomy were assayed by the newer methods in patients with medullaij thyroid carcinoma 
(MTC) diagnosed at initial testing (group I); in patients with early MTC diagnosed hy prospective 
screening (group ll); and in patients with pure C-cell hypei-ptasia detecied by pro.speclive screening 
(group III). At least 64% of group I. at least 25% of group II, but none of group III had detectable 
postoperative C-cell function. Conclusions: I) The previous estimate of 12 years as median age of 
onset of C-cell di.sea.se in MEN 2A is probably three to four years too old. 2) Patients diagnosed with 
early MTC by screening had not necessarily skipped a preneoplastic phase of C-cell hyperplasia. At 
least some early di.sease was not detected hy the standard assay. Higher .sensitivity assays should 
improve screening for C-cell disease by earlier disea.se detection. 3) Biochemical cure by thy-
roidectomy after the development of MTC is not as frequent as previously thought, but the apparent 
cure rate of pure C-cell hyperplasia remains 100%\ (Henry Ford Ho.sp Med J 1992:40:227-31) 
A large kindred with multiple endocrine neoplasia type 2A (MEN 2A), the J-kindred, has been the subject of a long-
term study begun in 1969 to identify individuals with C-cell dis-
ease and medullary thyroid carcinoma (MTC) in the preinvasive 
stage. The disease is inherited in autosomal dominant fashion 
with a theoretical probability that each child of a gene carrier has 
a50:50chance of developing MTC. During the first Iwo years of 
the study, 12 family members were found to have abnormal 
plasma calcitonin (CT) respon.ses to calcium infusion as mea-
sured by radioimmunoassay (1,2); each was operated upon and 
found to have MTC (3). A prospective study of individuals at 
risk was then initiated in which stimulated CT secretion was de-
termined at one- to two-year intervals. CT-secretion screening 
tests, with calcium as the secretagogue during the first few years 
and pentagastrin more recently, have identified many patients 
who have only C-cell hyperplasia or microscopic foci of carci-
noma in a gland with C-cell hyperplasia and who have no evi-
dence of metastatic disease (4-7). Similar studies have been re-
ported by other groups (8-10). By pooling test results frotn the 
J-kindred with a large number of other kindreds, it has also been 
possible to calculate the probability of developing C-cell dis-
ease as a function of age (11,12). Our screening protocol is 
started at 5 years of age for children at risk. C-cell abnormalities 
are assessed by annual CT measurernents before and after pen-
tagastrin stimulation; surgery is advised after two successive ab-
normal tests. Almost all family members so advised have had 
thyroidectomy within a few months. 
Although the majority of individuals with C-cell disease have 
been idendfied by prospective screening while in the premeta-
static stage, this program has not identified every patient in the 
preneoplastic stage. Of the individuals found to have developed 
C-cell disease during prospective screening between 1972 and 
1989.11 of 24 had intrathyroidal foci of medullary carcinoma at 
the time of surgery (6). This finding suggests that the premalig-
nant phase of C-cell hyperplasia (7) is absent or lasts less than 
two years in some affected persons, or, altematively, that the 
screening test might be too insensitive to detect the earliest 
stages of C-cell hyperplasia. Another uncertainty is that the like-
lihood of cure by total thyroidectomy and central node dissec-
tion, the standard surgical procedure for C-cell disease (13,14), 
is not known for tho.se patients treated after they develop local-
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ized foci of medullary carcinoma. Since most patients survive 
for many decades with known residual MTC, CT measurements 
must be used as surrogates for mortality data. 
The CT radioimmunoassay (1,2) used since the inception of 
the J-kindred screening program has a sensitivity of 100 to 200 
pg/mL. Two additional CT assays have become available that 
have .sensidvity limits of about 10 pg/mL. It was anticipated that 
the use of more sensitive assays might permit the detecdon of af-
fected individuals with C-ced disease at an earlier stage. Since 
1986, results from these newer assays have been compared with 
results obtained with the standard assay in screening the J-kin-
dred and another MEN 2A family, the C-kindred. By the use of 
the new CT assays in the prospective screening program and 
from measurements of CT in archived frozen serum samples 
from the J-kindred, evidence has emerged that the age of onset 
of C-cell hyperplasia may be earlier than previously thought, 
and that the cure rate in patients with minute foci of MTC may 
not be as high as our earlier findings indicated. These findings 
have important implicadons about the biology of MEN 2A and 
must be taken into account when calculadng risks of genetic 
susceptibility when used in conjunction with analysis of poly-
morphic gene markers (15-18). 
Patients and Methods 
The J-kindred has been described in detail (3-7). The C-kin-
dred, another MEN 2A family, is of French origin with family 
members living in France, the Quebec province of Canada, and 
Massachusetts with MTC occurring in three generations. Two 
affected individuals also have had pheochromocytomas and an-
other affected woman is said to have had bilateral adrenal tu-
mors, although documentation of her adrenal pathology is un-
available. No C-kindred member is known to have parathyroid 
disease. We have studied one branch of the C-kindred since 
1988. All patients in this study who have been treated surgically 
have had a total thyroidectomy and central node dissection. 
The pentagastrin stimuladon test consists of an intravenous 
bolus injection of pentagastrin (Peptavlon, Ayerst), 0.5 (J-g/kg 
body weight, with blood samples taken immediately before and 
1, 2, and 5 minutes afterward. 
The standard CT radioimmunoassay has been described 
(1,2). Upper limits of normal for basal- and pentagastrin-stimu-
lated serum CT concentrations are 550 pg/mL and 750 pg/mL, 
respecdvely. The newer assays are a commercially available kit 
from Nichols Institute Diagnostics (San Juan Capistrano, CA) 
and a kit commercially available in Europe from Intemational 
CIS (Gif-sur-Yvette, France). The Nichols assay is based on an-
tiserum from a goat immunized with synthetic human CT (19) 
and is a competitive radioimmunoassay. The sensitivity for this 
assay is 1 to 3 pg/mL. The upper limits of normal for basal se-
rum CT concentrations, as given by the manufacturer, are 36 pg/ 
mL for males and 17 pg/mL for females. The upper limits of nor-
mal for serum CT concentrations after pentagastrin stimulation, 
as given by the manufacturer, are 106 pg/mL for males and 29 
pg/mL for females. Basal semm CT concentrations were found 
to be above the lower limit of sensitivity in > 99% of our sam-
ples assayed with the Nichols kit. Most patients treated by total 
thyroidectomy had basal serum CT values of < 10 pg/inL by the 
Nichols assay with no change after pentagastrin injection. 
The CIS assay is a sandwich assay using two monoclonal an-
tibodies raised against a synthetic pepude with 1 to 32 amino 
acid sequence of the mature monomeric form of hurnan CT 
(20,21). The sensitivity for the CIS assay is 6.7 pg/mL. Using 
the CIS assay, both norrnal males and normal females have basal 
values < 10 pg/mL and values up to 30 pg/mL after pentagastrin 
stimulation [(22) and manufacturer's package information]. In 
our studies, 39 (83%) of 47 clinically unaffected members ofthe 
J- and C-kindreds were found to have basal serum CT values be-
low 6.7 pg/mL, and 44 (94%) of 47 had values < 10 pg/mL. 
Three males from unaffected branches of the J-kindred had 
slightly elevated basal serum CT concentrations of 16 to 39 pg/ 
mL, but showed no rise after pentagastrin stimulation. The pos-
sible significance ofthese values is discussed later. 
Padents with C-cell disease were considered to have a bio-
chemical cure after total thyroidectomy when both their basal 
and peak pentagastrin-stimulated serum CT concentrations 
were less than 10 pg/mL, or when their basal CT level was be-
tween 10 and 20 pg/mL and less than a 50% increa.se occurred 
after pentagastrin stimulation. In some patients, the Nichols and 
CIS assays gave discrepant results, and only basal serum CT 
measurements were available in one case; the findings in these 
cases will be noted specifically. 
Archived samples used for retrospective analysis were slored 
al -70 °C and had, in most cases, been thawed only once at the 
time oftheir initial measurements by the standard assay. 
Results 
Comparison of values obtained by the Nichols and CIS 
assays 
CT concentrations by both of the high-sensidvity assays were 
compared in 227 serum samples taken from 60 pentagastrin 
stimulation tests in which the CIS assay gave a measurable 
value. Most ofthese samples were from known affected individ-
uals, inasmuch as most known unaffected individuals had inde-
terminate values by the CIS assay. Values obtained with the 
Nichols assay were higher than those obtained with the CIS as-
say in 85% of samples. The mean rado of Nichols:CIS values 
was 1.38, with 95% confidence limits of 1.22 to 1.56 for the 
mean. Values from both assays were highly correlated from < 10 
to > 2,000 pg/mL, with r = 0.845 for log transformed values, P < 
0.0001. 
Sixty-seven samples were available in which serum CT con-
centradon was measurable by the standard assay and in which 
values from the other two assays were determined. Using log-
transformed data, the correlation between the values from the 
standard assay between 210 and 14,000 pg/mL and Nichols as-
say values was r = 0.585 (P < 0.001) and between standard assay 
and CIS assay values was r = 0.615 (P< 0.001). Values from the 
Nichols assay were up to 45% higher than those from standard 
assay in seven samples and were lower in the other 60. Values 
from the CIS assay were lower than those from the standard as-
say in all samples but one, in which the values were equal. 
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Clinical observations 
CT measurements in preoperative serum samples—Between 
1986 and 1989, three individuals were found to have abnormal 
CT secretory response results which revealed clinically impor-
tant discrepancies among the assays. One of these (Figure) was 
a 17-year-old female who had been screened regularly since age 
7 and had normal basal CT levels and pentagastrin-stimulated 
CT levels by the standard assay in every test. In archived serum, 
her basal and sdmulated CT values by the Nichols assay were, in 
retrospect, normal through age 12'/2 years. Over the next year 
there was a sharp rise to an abnormal level in the stimulated CT 
value, measured by the Nichols assay, with further increases 
during the following three years. In the last test, the basal serum 
CT concentration by the Nichols assay was only minimally ele-
vated (22 pg/mL), although the pentagastrin-sfimulated level 
was as much as six times normal. Basal serum CT concentra-
fions measured by the CIS assay (normal < 10 pg/mL) were 
slightly elevated in all available samples: the basal values were 
15 pg/inL at age 7, 29 pg/mL at age 17, and between 10 and 35 
pg/mL in the intervening tests (values not shown in the Figure). 
The stimulated-serum CT concentradons were also abnormal by 
the CIS assay in all of the avadable samples, but the elevations 
were minimal through age 12'/2. Like the Nichols assay, the CIS 
assay showed a marked rise in stimulated-serum CT levels 
thereafter. Total thyroidectomy was performed at age 17'/2; C-
cell hyperplasia with several small medullary carcinomas, up to 
5 mm in diameter, were found within the thyroid gland. 
Two other patients had results similar to the paUent illustrated 
in the Figure, although one had been lost to the study and had 
had no tests for five years before surgery. Retrospective mea-
surements by the newer assays showed marked elevations of 
sdmulated-serum CT concentrations for three to four years dur-
ing which the standard assay had given normal values. Both 
glands showed C-cell hyperplasia and small bilateral foci of 
MTC. 
Postoperative serum CT measurements— I^ndividuals with 
pathologically proven C-cell disease were classified into three 
groups for analysis of the biochemical outcome of surgery. 
Group I included 17 J-kindred and C-kindred members who 
had abnormal pentagastrin tests the first time they were tested 
(i.e., before prospective screening). The first tests in the J-kin-
dred members used the standard assay, while the finst tests in the 
C-kindred members used the Nichols assay. In this group, three 
patients died of causes unrelated to their MEN 2A diseases be-
fore our use ofthe Nichols and CIS assays. Of the other 14, four 
met criteria for biochemical cure, and 10 had clearly measurable 
postoperative semm CT concentrations by both the Nichols and 
CIS assays. In five ofthe 10, the basal serum CT concentrations 
were normal by both assays, with only the pentagastrin-stimula-
tion test showing evidence of residual C-cell function (stimu-
lated values between 36 and 450 pg/mL). One other of those 
with measurable serum CT postoperatively had advanced renal 
failure, and basal seruin CT concentrations > 100 pg/mL, but 
less than a 50% increment after pentagastrin sdmulation. Be-
cause renal fadure is known to cause elevated serum CT concen-
trafions in the absence of C-cell disease, the meaning of the ele-
vated level in this padent is unclear. Thus, nine of 14 tested pa-
E 
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Figure—Serum CT concentrations in a female J-kindred mem-
her measured in archived serum samples. Samples were stored 
at-70 °C f'or 1 month to 10 years before the measurements were 
performed. Stimulated values for each pentagastrin test are the 
highest ofthe values in the serum samples taken 1,2, and 5 min-
utes after pentagastrin injection. The horizontal litie indicates 
the upper limit of normal for stimulated values in females hy the 
Nichols assay. The upper limit of normal for stimulated values 
by the CIS assay is 10 pg/mL. Solid circles and squares denote 
basal and .stimulated values, respectively, hy the Nichols assay. 
Open circles denote stimulated values hy the CIS assay. For vi-
sual clarity, basal concentrations hy the CIS assay are not 
shown, hut are discussed in the text. 
tients in group I did not achieve biochemical cure after total thy-
roidectomy and the status of one is uncertain, although only two 
had known anatomic sites of residual MTC. The median time 
between surgery and the most recent CT testing was 18 years 
(range 1 to 21 years). 
Group II included 12 J-kindred padents whose abnormality 
was found by prospective screening and who had at least one 
microscopic focus of MTC at the time of thyroidectomy. All 
were tested with the newer CT assays postoperafively, with a 
median time between surgery and the most recent CT testing of 
13.5 years (range 1 to 16 years). Seven met the criteria for bio-
chemical cure by both the Nichols and CIS assays. Two met cri-
teria for biochemical cure by the CIS assay but had detectable 
pentagastrin-sfimulated CT levels by the Nichols assay (18 pg/ 
mL and 53 pg/mL). The other three had detectable basal- and 
stimulated-serum CT concentrations by both assays (basal val-
ues between 12 and 37 pg/mL, stimulated values between 33 
and 293 pg/mL). Of the three patients who had evidence of C-
cell disease several years before surgery when their archived se-
rum samples were retrospectively tested, one had residual C-cell 
function according to the Nichols assay and the other two had 
residual C-cell function by both assays. 
Group III included 13 J-kindred patients whose abnormality 
was found by prospective screening and who had only C-cell 
hyperplasia at the time of thyroidectomy. The median length of 
time between thyroidectomy and the most recent CT testing was 
15 years (range 7 to 18 years). In group III , two patients were 
lost to follow-up, eight met criteria for biochemical cure by both 
assays, and two met criteria for biochemical cure by the Nichols 
assay but were not tested by the CIS assay. The remaining 
woman had a normal basal-serum CT concentration by both as-
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says but did not receive pentagastrin because she was pregnant. 
Thus, in group III, no patient had evidence of abnormal residual 
C-cell function after surgery, although follow-up was incom-
plete. 
Discussion 
In this study, two high-sensitivity CT immunoassays were 
applied to the screening of individuals in MEN 2A kindreds for 
thyroid C-cell disease and results compared with studies using a 
standard assay. Both newer assays are capable of measuring se-
rum CT concentrations 10- to 30-fold lower than the sensitivity 
limit of the CT assays available prior to about 1986, including 
the standard assay used in screening the J-kindred since 1969. 
The results obtained with the Nichols and CIS assays were qual-
itatively similar, though some quanfitadve differences were 
found. The Nichols assay gave results that were generally higher 
than those of the CIS assay. This finding is not surprising. The 
Nichols assay uses an antiserum raised against synthetic human 
CT, which may well recognize not only the intact form of CT but 
other molecular species as well. The CIS assay is designed to 
measure only the mature, amidated monomeric form of CT 
which accounts for less than half of the total immunoreactive 
hormone in the circulation under basal conditions. The mature 
monomer predominates in the seruin of patients with MTC after 
pentagastrin .stimulation (23). The CIS assay detects CT in some 
padents who have renal failure or various neuroendocrine, lung, 
and other malignancies (24); CT precursors do not crossreact in 
the assay (25). Three unaffected men in our MEN 2A kindreds 
had slighdy elevated basal CT levels by the CIS assay, with no 
significant rise after pentagastrin. All are clinically well, though 
they may conceivably have an undetected disease that raises the 
semm CT level, or have semm constituents, other than CT, that 
interfere in the CIS assay. It would appear that the standard CT 
assay recognizes more forms of the circulating hormone than ei-
ther of the other methods. 
Semm CT measurements in archived preoperative serum 
samples from MEN 2A padents with proven C-cell disease sug-
gest that several affected individuals had developed abnormal 
C-cell function three to four years before detection by the stan-
dard assay. Similarly, Guilloteau et al (22), using the CIS assay 
to study one MEN 2A kindred, identified four cases of MTC in 
whom an older competitive radioimmunoassay method did not 
detect any abnormality. Thus, previous estimates of the age of 
onset of C-cell disease in MEN 2A may be too high by three to 
four years or more; the median age of onset may be closer to 8 or 
9 years than 12 years (11,12). Consequently, negative test re-
sults by a high-sensitivity CT assay may provide more reassur-
ance to a young adult than could be given with the previously 
available assays. For example, a 26-year-old individual with a 
normal pentagastrin test is probably closer to having a 5% risk 
of carrying the MEN 2A gene than the 10% risk previously esfi-
mated (11,12). 
Another implicadon ofthe retro.spective measurements is that 
the presence of intrathyroidal foci of MTC in about 50% of the 
J-kindred at the dme of surgery is likely to reflect the fact that 
clear elevations in serum CT in the earliest stages of C-ceU dis-
ease were not detected by the previously available assays. It is 
likely, therefore, that a higher percentage of patients will be 
identified in the premalignant phase of their C-cell disease when 
high-sensidvity CT assays are employed. Even with the in-
creased sensitivity of the newer serum CT assays, it is still the 
case that pentagastrin stimulation reveals abnormal C-cell func-
don up to several years before the basal serum CT concentration 
becomes abnormal (2-7). 
Resuhs from the high-sensitivity CT assays also modify pre-
vious conclusions (6) about the impact of total thyroidectomy 
on C-cell disease in MEN 2A. With the criteria we used for bio-
chemical cure, group III individuals with pure C-cell hyperpla-
sia treated by total thyroidectomy have an excellent cure rate. 
None tested thus far has evidence of residual abnormal C-cell 
function, though follow-up is incomplete. At the other extreme, 
only four of 14 group 1 patients, in whom MTC was present at 
initial testing before prospecdve screening began, met current 
criteria for biochemical cure. Since only one padent was cured 
of the three who died before we started using the newer assays, 
and one living patient has an uncertain status, the overall cure 
rate in this group is only about one-third. Previous esdmates us-
ing the standard CT assay, supplemented by the Nichols assay in 
a few patients, were that half of the patients in this group were 
cured (6). 
In group II patients, who had intrathyroidal MTC and C-cell 
hyperplasia detected by prospective screening, results of high-
sensitivity CT testing suggest that a substantial minority of pa-
tients fail to achieve biochemical cure after total thyroidectomy. 
There were three or five such cases out of 12 depending on the 
significance attached to detectable stimulated-serum CT levels 
by the Nichols assay only. The reason that this conclusion dif-
fers from previously reported findings in the J-kindred (6) is that 
three of the five individuals in this group with evidence of resid-
ual C-cell function had their abnormality detected and the other 
two had their first abnormal follow-up tests after the previous 
analysis was completed. 
The significance of postoperative residual C-cell function in 
relation to prognosis is not yet known. The group II patients who 
had detectable CT concentrations were 20 to 27 years old at the 
time ofthis analysis and had no other evidence of residual MTC. 
In the oldest generation of the J-kindred studied (diagnosed be-
fore any screening was started), five of seven affected individu-
als died of MTC, with ages at death of 51 to 69 years. Thus, diag-
nosis and treatment of C-cell disea.se in MEN 2A at the stage of 
C-cell hyperplasia appears to be the most effecdve manage-
ment, but diagnosis and treatment in the stage of microscopic in-
trathyroidal MTC is probably advantageous also. However, an 
additional 40 years of observation may be needed to provide a 
direct test of this hypothesis. 
On the basis of our findings, we recommend the use of high-
sensitivity CT assays in MEN 2A screening programs. Admit-
tedly, the frequency of a false-positive diagnosis when these 
tests are used is as yet unknown. Prospective screening is partic-
ularly demanding in this regaid, because the goal is diagnosis 
early in the course of the disorder. Using the standard assay, 
there has been one definite false-posidve diagnosis in 36 pa-
tients subjected to thyroidectomy in the J-kindred and three ad-
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didonal patients (included in our group III) whose thyroid histo-
pathology was mild diffuse C-cell hyperplasia but whose ge-
nefic linkage studies (16) predict a probability of less than 1% 
that they carry the MEN 2A gene (26). To date, seven untreated 
patients had abnormal pentagastrin tests by the newer CT as-
says. Ad had subsequent thyroidectomy; histopathology was 
microscopic MTC in four and diffuse C-cell hyperplasia in 
three. Thus, diagnosfic accuracy of these high-sensitivity assays 
is excellent so far, but only a small number of patients have had 
surgery to date. The combination of genetic screening for the 
MEN 2A carrier state (15-18), when it becomes available, to-
gether with a high-sensifivity CT assay in prospective screening 
programs, should lead to greater accuracy in the preoperative di-
agnosis of C-cell disease than either method alone. 
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